Denna annons är inte tillgänglig!
Umeå universitet är ett av Sveriges största lärosäten med över 37 000 studenter och cirka 4 700 anställda. Vid universitetet finns en mångfald av utbildningar av hög kvalitet och världsledande forskning inom flera vetenskapsområden, och här gjordes den banbrytande upptäckten av gensaxen CRISPR-Cas9 som tilldelats Nobelpriset i kemi. Vid Umeå universitet är allt nära. Våra sammanhållna campus gör det lätt att mötas, samarbeta och utbyta kunskap, något som gynnar en dynamisk och öppen kultur.
Den samhällsomvandling och de stora gröna investeringar vi ser i norra Sverige skapar enorma möjligheter och komplexa utmaningar. För Umeå universitet handlar det om att bedriva forskning om – och mitt i – ett samhälle i omvandling. Men också om att leverera utbildningar för regioner som behöver expandera fort och hållbart. Det är helt enkelt här framtiden skapas.
Är du intresserad av att veta mer? Läs mer om Umeå universitet som arbetsplats.
Forskargrupperna Anders Olofsson (inst. medicinsk biokemi och biofysik) och Intissar Anan (inst. folkhälsa och klinisk medicin) söker en postdoktor som under två års heltidsarbete ska fokusera på transtyretinamyloidos. Forskningsarbetet sker i en internationell miljö. Beskrivning av projektet och arbetsuppgifter är därför formulerade på engelska.
A main focus is to investigate the ability to inhibit production of transthyretin (TTR) in the eye by the CRISPR/Cas9 technique. The project will also involve multivariate analysis of biomarkers from patient samples as well biochemical and biophysical studies on to elucidate its interfering mechanism with other amyloid-forming polypeptides such as amyloid β, involved in Alzheimer’s disease and IAPP/amylin, linked to development of diabetes type II.
Projects
Amyloid formation resulting in depositions of protein fibrils in various tissues is a characteristic feature of in total 29 different human disorders including Alzheimer’s disease (AD), diabetes type II and familial amyloidosis with polyneuropathy. Amyloid disorders is in essence caused by an imbalance between the pathological self-assembly and clearance of the formed aggregates. Many different factors are however known to affect this balance and the cause should be considered multifactorial. A striking notion is that also very small alterations in this equilibrium can be detrimental and that a delicate balance separates healthy individuals from developing the disease. Amyloid formation from TTR is linked to a few disorders with similar pathology including familial amyloidosis with polyneuropathy, familial amyloidosis with cardiomyopathy and senile systemic amyloidosis. TTR however belongs to one of the few amyloid disorders where efficient treatments today can be offered. These includes either stabilization of the protein using small-ligands, which reduces its ability to form amyloid, as well as reducing the actual protein expression using RNAi based techniques targeting the liver which represents the main source of TTR production in the body. TTR is however also expressed in the restina of the eye and here amyloid deposits frequently results in opacities and reduced vision of the affected individuals. Current therapeutics cannot reach the retina of the eye and an aim with this project is to investigate the possibility to use CRISPR/Cas9 technique to knock-down production of TTR in the eye and hence eliminate the local protein production. If successful this would result in a single use treatment that effectively would block further amyloid formation.
Interestingly, TTR also displays anti-amyloidogenic features which raise the question about its physiological role in vivo apart from its known function as a transport protein for thyroxine-hormone and retinol binding protein. A part of the project will be focused on the interaction between TTR and amyloid-β (Aβ) linked to Alzheimer’s disease as well as the interaction between TTR and the islet amyloid polypeptide (IAPP) linked to development of diabetes type II. Here the aim is to elucidate the properties of TTR required for its amyloid interfering properties. The techniques involves protein and peptide purification, fluorescence studies to monitor amyloid formation and the probing of protein interactions using surface plasmon resonance.
You will:
Essential
Desirable
Qualification Requirements for appointment as Post-doctor
A person who has been awarded a doctorate or a foreign qualification deemed to be the equivalent of a doctorate shall be qualified for employment as a post-doctor. Priority should be given to candidates who have completed their doctoral degree no more than three years before the closing date of the application. A candidate who has completed their degree prior to this may be considered if special circumstances exist. Special circumstances include absence due to illness, parental leave or clinical practice, appointments of trust in trade union organizations or similar circumstances. Post-doctors who are to teach or supervise must have taken relevant courses in teaching and learning in higher education.
We are working in an international environment at the Department of public health and clinical medicine and Department of Medical Biochemistry and Biophysics at Umea University, Sweden. We offer an international, stimulating and collaborative research environment, in which your scientific career development is fostered.
Annonsen ska inkludera
https://www.umu.se/en/research/groups/anders-olofsson/
https://www.umu.se/forskning/projekt/patogenes-diagnostik-och-behandling-av-transtyretinamyloidos/
Anställningsform | Tidsbegränsad anställning |
---|---|
Anställningens omfattning | Heltid |
Antal lediga befattningar | 1 |
Sysselsättningsgrad | 100% |
Ort | Umeå |
Län | Västerbottens län |
Land | Sverige |
Referensnummer | AN 2.2.1-581-19 |
Kontakt |
|
Sista ansökningsdag | 2019-04-24 |